Αρχική World News Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with FGFR...

Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with FGFR Amplifications

New insights into the clinical benefit of fibroblast growth factor receptor (FGFR) inhibitor treatment according to the FGFR alterations occurring in several different cancer types that may help guide clinical decisions were presented at the ESMO Targeted Anticancer Therapies (TAT) Virtual Congress 2021 held on March 1-2, 2021.

Cédric Pobel of the DITEP, Institut Gustave Roussy in Villejuif, France explained that FGFR alterations including amplification, fusion and mutation are found in several cancer types, but the exact alterations that affect clinical efficacy of FGFR inhibitors have yet to be clarified.

Patients with several tumour types were included in the analysis

To this end, Dr. Pobel and co-investigators retrospectively assessed data from patients treated with pan-FGFR inhibitors in phase I/II trials at the Gustave Roussy from February 2011 to June 2020. Data from the JnJ-42756493 (NCT01703481; published May 2019), 14 BGJ-398 (NCT01004224; published November 2016), TAS-120 (NCT02052778; published July 2020), and INCB-54828-202 (NCT02924376; published July 2020) studies were included.

The cohort included 92 patients; of these, the most frequent tumour types were urothelial cancer, which occurred in 23.9% of patients, cholangiocarcinoma in 21.7%, breast cancer in 20.7%, and central nervous system cancer in 13%.

Among these patients, 22 had FGFR amplification, 33 had FGFR fusion, and 37 had FGFR mutation. Patients with an amplification tended to be younger with a median age of 43 years (p = 0.02) and patients with a mutation were older with a median age of 60.5 years (p = 0.03), as compared to patients with other FGFR alterations.

Patients with FGFR amplifications demonstrated shorter survival and lower response rates

Patients with an amplification demonstrated shorter progression-free survival (PFS) compared to patients with other alterations; median PFS was 2.23 months in the amplification cohort compared to 5.23 months in patients with other alterations (hazard ratio [HR] 2.64, 95% confidence interval [CI] 1.55-4.51; p < 0.01).

Patients with an FGFR fusion experienced prolonged PFS compared to those with other alterations of median 6.20 months versus 2.70 months, respectively (HR 0.61; 95% CI 0.38-0.98; p = 0.04).

Similar PFS was observed in patients with FGFR mutation compared to other alterations of median 2.77 months versus 3.67 months, respectively (HR 0.91; 95% CI 0.57-1.44; p = 0.70).


Progression-free survival is shorter for patients with a FGFR amplification treated by pan-FGFR inhibitors compared to fusion and mutation.

© Cédric Pobel.

No significant difference in overall survival was found.

The best response in the FGFR amplification, fusion, and mutation cohorts was partial response, which was observed in one (4.5%), 13 (39.4%), and 10 (27%) patients, respectively (p = 0.03). In the respective cohorts, stable disease was achieved by 14 (63.6%), 12 (36.4%), and 17 (45.9%; p = 0.10) patients, whereas 7 (31.8%), 8 (24.2%), and 10 (27.0%) patients experienced disease progression (p = 0.80).


Based upon this analysis of data from several clinical studies, the authors concluded that the clinical benefit of FGFR inhibition is stronger in patients with an FGFR fusion or mutation compared to FGFR amplification.

According to the investigators, the role of pan-FGFR inhibitors in amplified tumours remains unclear and requires further investigation.

This study did not receive external funding.


34MO – Pobel C, Facchinetti F, Bahleda R, et al. Outcomes according to FGFR alteration types in patients with a solid tumour treated by a pan-FGRF tyrosine kinase inhibitor in phase I/II trials. ESMO Targeted Anticancer Therapies (TAT) Virtual Congress (1-2 March 2021).



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...